Neil Rosenshein, MD
Gynecologic Oncology · Baltimore, MDNPI 1134162738
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,185 of the $4,754 with a category attached, or 67.0%. Merck accounts for 81.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $4,295 and has fallen 97.8% since, to $94 in 2024.
Across 36 payments — averaging $132.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4K
- Baxter Healthcare$293
- Clovis Oncology, Inc.$147
- Aspira Women's Health Inc$94
- Foundation Medicine, Inc.$84
- Tactile Systems Technology Inc$69
- plus $175 from 8 others
What the payments were for
- Speaking & faculty fees$3,18567%
- Travel & lodging$58212%
- Food & beverage$87518%
- Education$1122%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 3 | $3,890 |
| Baxter Healthcare | 4 | $293 |
| Clovis Oncology, Inc. | 5 | $147 |
| Aspira Women's Health Inc | 6 | $94 |
| Foundation Medicine, Inc. | 5 | $84 |
| Tactile Systems Technology Inc | 4 | $69 |
| Tesaro, Inc. | 2 | $49 |
| Convatec Inc. | 1 | $26 |
| KCI USA, Inc. | 1 | $22 |
| Smith+Nephew | 1 | $19 |
| Avanos Medical | 1 | $17 |
| AbbVie | 1 | $15 |
| Millicent US Inc | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,754 in reported general payments places this provider in the 75th percentile of 35 gynecologic oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 48 | $29,813 |
| Estradiol | 296 | $27,247 |
| PremarinEstrogens, Conjugated | 19 | $12,140 |
| YuvafemEstradiol | 27 | $4,398 |
| Tolterodine Tartrate ErTolterodine Tartrate | 47 | $2,926 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 177 | $2,907 |
| Estradiol (Twice Weekly)Estradiol | 22 | $2,424 |
| Clobetasol Propionate | 40 | $1,368 |
| Estradiol (Once Weekly)Estradiol | 11 | $1,296 |
| ValacyclovirValacyclovir Hcl | 25 | $1,115 |
| Anastrozole | 33 | $703 |
| Metronidazole | 19 | $421 |
| Megestrol Acetate | 15 | $396 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 29 | $347 |
| Fluconazole | 48 | $216 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Baltimore
- Dwight ImBaltimore$93K
- Amanda Nickles-FaderBaltimore$21K
- Kara Long RocheBaltimore$5K
- Sarah LynamBaltimore$3K
- Amanda RamosBaltimore$3K
- Beman KhulpateeaBaltimore$2K
- Dana RoqueBaltimore$2K
- Christine O ConnorBaltimore$1K
- Hyung RyuBaltimore$973
- Teresa Diaz-MontesBaltimore$887
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.